Dr. McDonald's full Initiation Report is available to download at no cost at the LifeSci Advisors website, www.lifesciadvisors.com. In addition to this Initiation Report, LifeSci Advisors will also provide ongoing coverage and event-based research updates on the Company as developments occur.
The LifeSci Advisors research team is led by Dr. Andrew I. McDonald, an industry veteran with more than 15 years of healthcare industry experience. Prior to co-founding LSA, Dr. McDonald was the Senior Biotechnology Analyst at Great Point Partners, a leading health care investment firm with over $500 million under management. Before Great Point, he was Co-Head of Healthcare Research and Lead Biotechnology Analyst at ThinkEquity Partners, a boutique investment banking firm focused on growth companies. Dr. McDonald holds a Ph.D. in organic chemistry from the University of California, Irvine, and, earlier in his career, worked as a medicinal chemist at both Pfizer and Cytokinetics.
About LifeSci Advisors:
LifeSci Advisors (LSA) is a leading research firm and communications consultancy dedicated to the life sciences industry. The firm provides strategic counsel, customized marketing communications, comprehensive research reports and investor relations services to companies that specialize in the discovery, development and commercialization of drugs, drug delivery systems, medical devices and diagnostics. To learn more about LSA, visit the company's website, www.lifesciadvisors.com.
Important Disclosures:
The research report described in this press release is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell securities. The securities discussed in LSA research reports may be unsuitable for some investors depending on their specific investment objectives, financial status, risk profile, or particular needs. Investors should consider LSA reports as only a single factor in making their investment decisions and should not rely solely on these reports in evaluating whether or not to buy or sell the securities of the subject company. LifeSci Advisors has been compensated by the company that is the subject of the report described and future research reports, investor relations services, and general consulting services. Please read each report's full disclosures and analyst background on the LSA website, www.lifesciadvisors.com, before investing. LifeSci Advisors is not a registered investment adviser or broker-dealer.
Forward-looking statements:
This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. These forward-looking statements represent LSA's judgment as of the date of this release. LifeSci Advisors disclaims, however, any intent or obligation to update these forward-looking statements.
Media Contact:
Michael Rice
Phone: (646) 597-6979
Email: mrice@lifesciadvisors.com
BrainStorm Cell Therapeutics Contact:
Alon Natanson
CEO
Phone: +972-3-9236384
info@brainstorm-cell.com
Most Popular Stories
- Summer Movie Forecast: Biggest Box Office Season Yet for 3D Movies
- Fox, Twitter Team Up to Promote TV Shows, Sell Ads
- One Hot Summer as Theater Season Opens
- Cinedigm and Universal Studios Home Entertainment Enter Into Multiyear Home Entertainment Distribution Relationship
- iPhone 6 'Appears' on Vodafone U.K. Store as '4G iPhone 6'
- Hispanics Wanted in STEM Careers
- Nikki Hill Brings Raw Energy to Roanoke
- Boman Modine Launches Kickstarter Campaign for Film About Cystic Fibrosis
- Guitar Center Sessions Updates on New Episodes Featuring The Smashing Pumpkins, Goo Goo Dolls, OneRepublic and Talib Kweli
- OSN Strengthens Regional Footprint With New Flagship Showroom in Kuwait
News-To-Go
Advertisement
Advertisement
News Column
LifeSci Advisors Initiates Coverage of Brainstorm Cell Therapeutics
Page 2 of 2
Source: Marketwire
1 | 2 | Next >>
Story Tools



